Ziccum AB Logo

Ziccum AB

ZICC | ST

Overview

Corporate Details

ISIN(s):
SE0011415595 (+3 more)
LEI:
5493005TADJBZHXP0U27
Country:
Sweden
Address:
Scheelevägen 22, 223 63 Lund
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Ziccum AB develops and licenses its proprietary drying technology, LaminarPace®. This platform uses mass transfer at ambient temperatures to formulate sensitive biologics and vaccines into thermostable, particle-engineered dry powders. The process avoids heat-related degradation, preserving the substance's efficacy and eliminating the need for complex cold chain logistics. The resulting powders are also suitable for novel administration routes. Ziccum's business model is focused on entering into license agreements and technology transfers with major pharmaceutical and biotherapeutic companies to integrate its technology into their product development and manufacturing.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Ziccum AB. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Ziccum AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Ziccum AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-12-13 Ann Gidner Other Buy 14,000 8,381.80 SEK

Peer Companies

Company Country Ticker View
ONCODESIGN Logo
Develops precision cancer therapies and diagnostics targeting resistance and metastasis.
France ALONC
Oncodesign Precision Medicine S.A Logo
Develops therapies & diagnostics for resistant and metastatic cancers.
France ALOPM
Oncoinvent ASA Logo
Developing alpha-emitting radiopharmaceuticals like Radspherin® for localized cancer treatment.
Norway OCIN
OncoZenge AB Logo
Developing a non-opioid lozenge for oral pain relief in cancer patients.
Sweden ONCOZ
Onxeo Logo
Developing precision therapies for complex diseases using a proprietary single-domain antibody platform.
France ALONX
OPTIBIOTIX HEALTH PLC Logo
Develops microbiome-modulating ingredients and supplements to manage chronic lifestyle diseases.
United Kingdom OPTI
Oramed Pharmaceuticals Inc. Logo
Developing oral drug delivery systems to replace injections, like an oral insulin capsule.
Israel ORMP
Oryzon Genomics S.A. Logo
Advancing epigenetic therapeutics for oncology and central nervous system disorders.
Spain ORY
OSE Immunotherapeutics Logo
Developing first-in-class immunotherapies for immuno-oncology and immuno-inflammation.
France OSE
Ovoca Bio Plc Logo
Clinical-stage biopharma developing novel treatments for female sexual dysfunction.
Ireland OVXA